Companies › Candel Therapeutics
1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Aglatimagene Besadenovec | – | Phase 3 | Prostate Cancer; Non-squamous, Non-Small Cell Lung Cancer; Prostate Cancer Patients Treated by Radiotherapy; Non Small Cell Lung Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02768363 | Aglatimagene Besadenovec | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT07332000 | Aglatimagene Besadenovec | Phase 2 | Prostate Cancer Patients Treated by Radiotherapy | Oncology | Feb 2027 |
| NCT04495153 | Aglatimagene Besadenovec | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT01436968 | Aglatimagene Besadenovec | Phase 3 | Prostate Cancer | Oncology | Dec 2030 |
| NCT07660094 | Aglatimagene Besadenovec | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer | Oncology | Oct 2031 |
Cash of $202m on 2026-06-30; operating cash outflow about $71m a year; runway about 34 months at that burn, to Apr 2029; 3 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Immutep S.A.S. ADC Therapeutics Actinium Pharmaceuticals Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.